American Assets Inc. Buys Shares of 125,000 Evolus, Inc. $EOLS

American Assets Inc. acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 125,000 shares of the company’s stock, valued at approximately $768,000. Evolus accounts for 0.2% of American Assets Inc.’s portfolio, making the stock its 14th biggest position. American Assets Inc. owned approximately 0.19% of Evolus at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of EOLS. Rice Hall James & Associates LLC grew its stake in Evolus by 17.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company’s stock worth $7,177,000 after buying an additional 172,846 shares during the last quarter. Pinnacle Associates Ltd. acquired a new stake in shares of Evolus in the second quarter valued at approximately $6,318,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Evolus during the second quarter valued at approximately $22,431,000. Frontier Capital Management Co. LLC boosted its position in shares of Evolus by 37.9% during the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock worth $15,333,000 after buying an additional 457,533 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Evolus during the second quarter worth approximately $434,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on EOLS shares. HC Wainwright reduced their price objective on shares of Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. BTIG Research cut their target price on Evolus from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Stifel Nicolaus decreased their price target on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Finally, Mizuho set a $15.00 price objective on shares of Evolus in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.50.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the transaction, the insider owned 354,388 shares in the company, valued at $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.90% of the stock is currently owned by company insiders.

Evolus Price Performance

NASDAQ:EOLS opened at $4.50 on Friday. Evolus, Inc. has a one year low of $4.41 and a one year high of $17.12. The company has a market cap of $291.69 million, a PE ratio of -4.89 and a beta of 1.11. The firm has a 50-day moving average of $6.01 and a 200-day moving average of $6.68.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. The business had revenue of $68.97 million during the quarter, compared to the consensus estimate of $91.23 million. On average, equities research analysts expect that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.